NEWS ANNOUNCEMENT

Scientists advance research towards new therapy for medulloblastoma

Dr. Xi Huang

Senior Scientist, Developmental & Stem Cell Biology

Dr. Xi Huang, Senior Scientist in the Developmental, Stem Cell & Cancer Biology program at The Hospital for Sick Children (SickKids), has published an exciting new update in his work to develop a novel therapeutic for medulloblastoma, the most common malignant brain tumour in children.

After completing extensive screening and investigation into the function of potassium channels in promoting tumour growth, Huang and his research team published findings in Developmental Cell that identify KCNB2 as a novel target for inhibiting tumour growth in medulloblastoma.

Read more about Huang’s research on SickKids.ca

Opportunity:

Huang has won two SickKids Proof of Principle grant competitions (2023, 2022)providing the funding required for a drug discovery campaign against KCNB2. Huang engaged with a specialized ion channel drug discovery company to evaluate the efficacy of over 30,000 small molecules pre-selected for their ability to pass the blood-brain barrier.

Huang is now investigating the therapeutic efficacy of the ranked molecules in preclinical animal models to identify lead candidates.

IP&C is seeking development partners to help advance selective inhibitors of KCNB2 towards the clinic. To learn more about how to get involved in this promising opportunity for cancer therapy, contact Kamran Rezai.

Share This Story!